Biogen and Sanofi are among the investors in a series A round closed by Yumanity Therapeutics, which plans to now advance its neurological disease treatment platforms.
US-based neurodegenerative disease treatment developer Yumanity Therapeutics completed a $45m series A round backed by investors including biotechnology producer Biogen and Sanofi-Genzyme BioVentures, a subsidiary of pharmaceutical firm Sanofi, today.
Financial services group Fidelity Management & Research Company led the round, which also featured Alexandria Venture Investments, a subsidiary of biotech real estate company Alexandria Real Estate Equities, as well as Redmile Group and Dolby Family Ventures.
Yumanity will use the funding to advance platforms that will form the basis…
